SIGNIFICANCE OF THE GLUTAMATE SYSTEM IN NEUROTIC PATHOLOGY

  2. 2023
  3. SIGNIFICANCE OF THE GLUTAMATE SYSTEM IN NEUROTIC PATHOLOGY

Sydorenko A. H.

SIGNIFICANCE OF THE GLUTAMATE SYSTEM IN NEUROTIC PATHOLOGY

Show/Download

About the author:

Sydorenko A. H.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

Every third Ukrainian suffers from an anxiety disorder. The help that patients receive is not always effective. The high prevalence of this disease and the insufficient effectiveness of the existing treatment require the need to study the pathogenesis of neuroses and look for new treatment methods. The work aims to show the role of the glutamate system in developing neurotic pathology. Glutamic acid is the primary excitatory neurotransmitter. It interacts with glutamate receptors (mGlu), divided into ionotropic and membranotropic. There are three groups of ionotropic receptors. Membranotropic glutamate receptors are divided into three subgroups of receptors. Some of them are presynaptic autoreceptors. The participation of the glutamatergic system in the pathogenesis of neuroses is evidenced by the fact that competitive NMDA agonists have anticonvulsant and neuroprotective properties, as well as an anxiolytic effect. NMDA receptors are closely related to neurological and psychiatric disorders, including neurodegenerative diseases, stroke, epilepsy, schizophrenia, Alzheimer's disease and Parkinsonism. AMPA glutamate receptors are the main mediators of fast excitatory neurotransmission in the central nervous system. They play an essential role in the occurrence of epileptic seizures. Metabotropic glutamate receptors (mGluRs) are a relatively new biotarget. The basis of the search for effective and safe drugs for treating anxiety is modulators of glutamatergic neurotransmission. The study of this system is necessary for understanding the pathogenesis and development of such common pathologies as anxiety, neurosis, depression, epilepsy, addiction, and neurodegenerative diseases.

Tags:

anxiety disorder, glutamate receptors, glutamic acid, neurosis

Bibliography:

  1. Huprich SK, Malone BC. Malignant Self-Regard: Overview and Future Directions. Harv Rev Psychiatry. 2022;30(4):226-237. DOI: 10.1097/ HRP.0000000000000342.
  2. Tibrewal P, Looi JCL, Allison S, Bastiampillai T. Benzodiazepines for the long-term treatment of anxiety disorders? Lancet. 2021;398(10295):119-120. DOI: 10.1016/S0140-6736(21)00934-X.
  3. Penninx BWJH, Pine DS, Holmes EA, Reif A. Benzodiazepines for the long-term treatment of anxiety disorders? – Authors’ reply. Lancet. 2021;398(10295):120. DOI: 10.1016/S0140-6736(21)00931-4.
  4. Wang YT, Zhang NN, Liu LJ, Jiang H, Hu D, Wang ZZ, et al. Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants. Biochem Biophys Res Commun. 2022;594:46-56. DOI: https://doi. org/10.1016/j.bbrc.2022.01.024.
  5. Limandri BJ. Lumateperone: new drug or same old drug with a new dress? J Psychosoc Nurs Ment Health Serv. 2020;58(6):9-12. DOI: 10.3928/ 02793695-20200513-01.
  6. Areal LB, Hamilton A, Martins-Silva C, Pires WRG, Ferguson SSG. Neuronal scaffolding protein spinophilin is integral for cocaine-induced behavioral sensitization and ERK1/2 activation. Mol Brain. 2019;12(1):15. DOI: 10.1186/s13041-019-0434-7.
  7. Hart M, Diener C, Lunkes L, Rheinheimer S, Krammes L, Keller A, et al. miR-34a-5p as molecular hub of pathomechanisms in Huntington’s disease. Mol Med. 2023;29(1):43. DOI: 10.1186/s10020-023-00640-7.
  8. García-Alandete J. Rudolf Allers’ conception of neurosis as a metaphysical conflict. Hist Psychiatry. 2020;31(1):21-36. DOI: 10.1177/0957154X198 77295.
  9. Citkowska-Kisielewska A, Rutkowski K, Sobański JA, Dembińska E, Mielimąka M. Anxiety symptoms in obsessive-compulsive disorder and generalized anxiety disorder. Psychiatr Pol. 2019;53(4):845-864. DOI: 10.12740/PP/105378.
  10. Sirakanyan SN, Spinelli D, Geronikaki A, Kartsev V, Hakobyan EK, Petrou A, et al. Synthesis and Neurotropic Activity of New Heterocyclic Systems: Pyridofuro[3,2-d]pyrrolo[1,2-a]pyrimidines, Pyridofuro[3,2-d]pyrido[1,2-a]pyrimidines and Pyridofuro[3’,2’:4,5]pyrimido[1,2-a] azepines. Molecules. 2021;26(11):3320. DOI: https://doi.org/10.3390/molecules26113320.
  11. Guo C, Ma YY. Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders. Front Neural Circuits. 2021;15:711564. DOI: 10.3389/fncir.2021.711564.
  12. Huang Z, Niu L. RNA aptamers for AMPA receptors. Neuropharmacology. 2021;199:108761. DOI: 10.1016/j.neuropharm.2021.108761.
  13. Kamalova A, Nakagawa T. AMPA receptor structure and auxiliary subunits. J Physiol. 2021;599(2):453-469. DOI: 10.1113/JP278701.
  14. Pampaloni NP, Plested AJR. Slow excitatory synaptic currents generated by AMPA receptors. J Physiol. 2022;600(2):217-232. DOI: 10.1113/JP280877.
  15. Bissen D, Foss F, Acker-Palmer A. AMPA receptors and their minions: auxiliary proteins in AMPA receptor trafficking. Cell Mol Life Sci. 2019;76(11):2133-2169. DOI: 10.1007/s00018-019-03068-7.
  16. Pampaloni NP, Riva I, Carbone AL, Plested AJR. Slow AMPA receptors in hippocampal principal cells. Cell Rep. 2021;36(5):109496. DOI: 10.1016/j.celrep.2021.109496.
  17. Miao Y, Zhao G-L, Cheng S, Wang Z, Yang X-Li. Activation of retinal glial cells contributes to the degeneration of ganglion cells in experimental glaucoma. Prog Retin Eye Res. 2023;93:101-169. DOI: 10.1016/j. preteyeres.2023.101169.
  18. Shah A, Kury LA, Li T, Zeb A, Koh PO, Liu F, et al. Polydatin attenuates neuronal loss via reducing neuroinflammation and oxidative stress in rat MCAO models. Front Pharmacol. 2019;10:663. DOI: 10.3389/fphar.2019. 00663.
  19. Babaei P. NMDA and AMPA receptors dysregulation in Alzheimer’s disease. Eur J Pharmacol. 2021;908:1743-10. DOI: 10.1016/j. ejphar.2021.174310.
  20. Moore TJ, Alami A, Alexander GC, Donald R. Mattison Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy. 2022;42(7):567-579. DOI: 10.1002/phar.2707.
  21. Collingridge GL, Monaghan DT. The continually evolving role of NMDA receptors in neurobiology and disease. Neuropharmacology. 2022;210:1090-42. DOI: 10.1016/j.neuropharm.2022.109042.
  22. Zhou JJ, Shao JY, Chen SR, Pan HL. Calcineurin controls hypothalamic NMDA receptor activity and sympathetic outflow. Circ Res. 2022;131(4):345-360. DOI: 10.1161/CIRCRESAHA.122.320976.
  23. Kim KS, Jeon MT, Kim ES, Lee CH, Kim DG. Activation of NMDA receptors in brain endothelial cells increases transcellular permeability. Fluids Barriers CNS. 2022;19(1):70. DOI: 10.1186/s12987-022-00364-6.
  24. Kaidashev I, Shlykova O, Izmailova O, Torubara O, Yushchenko Y, Tyshkovska T, et al. Host gene variability and SARS-CoV-2 infection: A review article. Heliyon. 2021 Aug;7(8):e07863. DOI: 10.1016/j.heliyon. 2021.e07863.
  25. Chekalina NI, Shut SV, Trybrat TA, Burmak YH, Petrov YY, Manusha YI, et al. Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease. Wiad Lek. 2017;70(4):707-711.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 109-116 pages, index UDC 616.8 – 00:615.21

DOI:

10.29254/2077-4214-2023-2-169-109-116

2023 Issue 2, 169
anxiety disorder glutamate receptors glutamic acid neurosis
29.06.2023
Was this article helpful?
1
1